S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.55 (-1.13%)
AAPL   173.04 (-1.73%)
MSFT   312.36 (-1.63%)
META   298.85 (-0.66%)
GOOGL   128.30 (-2.14%)
AMZN   127.68 (-2.73%)
TSLA   246.57 (-0.17%)
NVDA   422.54 (+0.08%)
NIO   8.48 (+1.56%)
BABA   86.22 (-1.15%)
AMD   96.13 (-1.28%)
T   15.04 (-0.13%)
F   12.53 (-0.40%)
MU   68.36 (-0.32%)
CGC   0.94 (-0.31%)
GE   110.18 (-1.38%)
DIS   80.47 (-0.67%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.11 (+0.42%)
NFLX   381.22 (-0.93%)
S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.55 (-1.13%)
AAPL   173.04 (-1.73%)
MSFT   312.36 (-1.63%)
META   298.85 (-0.66%)
GOOGL   128.30 (-2.14%)
AMZN   127.68 (-2.73%)
TSLA   246.57 (-0.17%)
NVDA   422.54 (+0.08%)
NIO   8.48 (+1.56%)
BABA   86.22 (-1.15%)
AMD   96.13 (-1.28%)
T   15.04 (-0.13%)
F   12.53 (-0.40%)
MU   68.36 (-0.32%)
CGC   0.94 (-0.31%)
GE   110.18 (-1.38%)
DIS   80.47 (-0.67%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.11 (+0.42%)
NFLX   381.22 (-0.93%)
S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.55 (-1.13%)
AAPL   173.04 (-1.73%)
MSFT   312.36 (-1.63%)
META   298.85 (-0.66%)
GOOGL   128.30 (-2.14%)
AMZN   127.68 (-2.73%)
TSLA   246.57 (-0.17%)
NVDA   422.54 (+0.08%)
NIO   8.48 (+1.56%)
BABA   86.22 (-1.15%)
AMD   96.13 (-1.28%)
T   15.04 (-0.13%)
F   12.53 (-0.40%)
MU   68.36 (-0.32%)
CGC   0.94 (-0.31%)
GE   110.18 (-1.38%)
DIS   80.47 (-0.67%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.11 (+0.42%)
NFLX   381.22 (-0.93%)
S&P 500   4,293.50 (-1.01%)
DOW   33,735.48 (-0.80%)
QQQ   355.55 (-1.13%)
AAPL   173.04 (-1.73%)
MSFT   312.36 (-1.63%)
META   298.85 (-0.66%)
GOOGL   128.30 (-2.14%)
AMZN   127.68 (-2.73%)
TSLA   246.57 (-0.17%)
NVDA   422.54 (+0.08%)
NIO   8.48 (+1.56%)
BABA   86.22 (-1.15%)
AMD   96.13 (-1.28%)
T   15.04 (-0.13%)
F   12.53 (-0.40%)
MU   68.36 (-0.32%)
CGC   0.94 (-0.31%)
GE   110.18 (-1.38%)
DIS   80.47 (-0.67%)
AMC   8.05 (-1.11%)
PFE   32.89 (-0.27%)
PYPL   59.11 (+0.42%)
NFLX   381.22 (-0.93%)
NASDAQ:SNOA

Sonoma Pharmaceuticals (SNOA) Stock Forecast, Price & News

$0.80
+0.03 (+3.90%)
(As of 11:48 AM ET)
Compare
Today's Range
$0.76
▼
$0.83
50-Day Range
$0.76
▼
$1.16
52-Week Range
$0.76
▼
$3.34
Volume
1,674 shs
Average Volume
868,973 shs
Market Capitalization
$4.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.25
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Sonoma Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
306.3% Upside
$3.25 Price Target
Short Interest
Healthy
0.83% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.89) to ($0.45) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

See Top Rated MarketRank™ Stocks Here

SNOA stock logo

About Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

SNOA Price History

SNOA Stock News Headlines

August 15, 2023 | finance.yahoo.com
National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
August 10, 2023 | finanznachrichten.de
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial Results
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
August 10, 2023 | finance.yahoo.com
Sonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial Results
August 3, 2023 | finance.yahoo.com
Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory Board
June 22, 2023 | finanznachrichten.de
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2023 Financial Results
June 22, 2023 | finance.yahoo.com
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2023 Financial Results
June 9, 2023 | finance.yahoo.com
Sonoma Pharmaceuticals Shares Soar 44% After Introducing New Product
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
June 8, 2023 | finanznachrichten.de
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union
June 8, 2023 | finance.yahoo.com
Sonoma Pharmaceuticals Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union
May 21, 2023 | thestreet.com
Williams-Sonoma Could Be Headed for More Trouble
May 11, 2023 | marketwatch.com
8-K: Sonoma Pharmaceuticals, Inc.
April 19, 2023 | finance.yahoo.com
Benign Growth For Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Underpins Its Share Price
April 14, 2023 | travel.usnews.com
Getting Around Sonoma
April 12, 2023 | nytimes.com
Track Covid-19 in Sonoma County, California
April 11, 2023 | finanznachrichten.de
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Introduces Podiacyn, an All Natural, Over-the-Counter Podiatry Product for Daily Foot Care
April 11, 2023 | finance.yahoo.com
Sonoma Pharmaceuticals Introduces Podiacyn, an All Natural, Over-the-Counter Podiatry Product for Daily Foot Care
April 4, 2023 | travel.usnews.com
Sonoma Plaza
March 28, 2023 | finanznachrichten.de
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI North America Conference in Philadelphia
March 28, 2023 | finance.yahoo.com
Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI North America Conference in Philadelphia
March 28, 2023 | seekingalpha.com
Regeneron to pay Sonoma $75M upfront in pact to develop autoimmune disease drugs
March 2, 2023 | finance.yahoo.com
Sonoma Pharmaceuticals and MicroSafe Group Announce New EPA Claims and Green Seal Certification for Nanocyn(R) Hospital-Grade Disinfectant
February 14, 2023 | finanznachrichten.de
Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Third Quarter 2023 Financial Results
February 14, 2023 | finance.yahoo.com
Sonoma Pharmaceuticals Reports Third Quarter 2023 Financial Results
January 31, 2023 | finance.yahoo.com
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea
January 25, 2023 | benzinga.com
These Four Companies Are Attracting Investors Following Recent News
See More Headlines
Receive SNOA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNOA Company Calendar

Last Earnings
8/10/2023
Today
9/26/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
3/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNOA
CUSIP
N/A
CIK
1367083
Web
www.sonomapharma.com
Phone
(800) 759-9305
Fax
707-283-0551
Employees
9
Year Founded
1999

Price Target and Rating

Average Stock Price Forecast
$3.25
High Stock Price Forecast
$3.25
Low Stock Price Forecast
$3.25
Forecasted Upside/Downside
+306.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,150,000.00
Net Margins
-44.68%
Pretax Margin
-44.93%
Return on Equity
-65.44%
Return on Assets
-29.82%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.36
Quick Ratio
2.69

Sales & Book Value

Annual Sales
$13.27 million
Price / Sales
0.31
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.72 per share
Price / Book
0.47

Miscellaneous

Outstanding Shares
5,140,000
Free Float
4,670,000
Market Cap
$4.11 million
Optionable
Not Optionable
Beta
1.23

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Ms. Amy M. Trombly (Age 55)
    CEO, Pres & Director
    Comp: $524.19k
  • Mr. Jerome J. Dvonch (Age 55)
    Interim Chief Financial Officer
    Comp: $281.16k
  • Mr. Bruce Thornton (Age 59)
    COO & Corp. Sec.
    Comp: $448.87k
  • Mr. John Dal Poggetto (Age 51)
    Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













SNOA Stock - Frequently Asked Questions

Should I buy or sell Sonoma Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sonoma Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SNOA shares.
View SNOA analyst ratings or view top-rated stocks.

What is Sonoma Pharmaceuticals' stock price forecast for 2023?

1 Wall Street analysts have issued 1-year price objectives for Sonoma Pharmaceuticals' shares. Their SNOA share price forecasts range from $3.25 to $3.25. On average, they expect the company's share price to reach $3.25 in the next year. This suggests a possible upside of 306.3% from the stock's current price.
View analysts price targets for SNOA or view top-rated stocks among Wall Street analysts.

How have SNOA shares performed in 2023?

Sonoma Pharmaceuticals' stock was trading at $1.12 at the start of the year. Since then, SNOA stock has decreased by 28.6% and is now trading at $0.80.
View the best growth stocks for 2023 here.

Are investors shorting Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 42,700 shares, an increase of 42.3% from the August 15th total of 30,000 shares. Based on an average daily trading volume, of 501,900 shares, the short-interest ratio is presently 0.1 days.
View Sonoma Pharmaceuticals' Short Interest.

When is Sonoma Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our SNOA earnings forecast.

How were Sonoma Pharmaceuticals' earnings last quarter?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) issued its quarterly earnings data on Thursday, August, 10th. The company reported ($0.29) EPS for the quarter. The company had revenue of $3.43 million for the quarter. Sonoma Pharmaceuticals had a negative net margin of 44.68% and a negative trailing twelve-month return on equity of 65.44%.

What other stocks do shareholders of Sonoma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sonoma Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), VelocityShares Daily 2x VIX Short-Term ETN (TVIX), Sorrento Therapeutics (SRNE), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Amarin (AMRN), Pfizer (PFE), Nabriva Therapeutics (NBRV), Verastem (VSTM) and Vaxart (VXRT).

What is Sonoma Pharmaceuticals' stock symbol?

Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNOA."

Who are Sonoma Pharmaceuticals' major shareholders?

Sonoma Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Two Sigma Securities LLC (1.01%) and State Street Corp (0.47%).
View institutional ownership trends.

How do I buy shares of Sonoma Pharmaceuticals?

Shares of SNOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sonoma Pharmaceuticals' stock price today?

One share of SNOA stock can currently be purchased for approximately $0.80.

How much money does Sonoma Pharmaceuticals make?

Sonoma Pharmaceuticals (NASDAQ:SNOA) has a market capitalization of $4.11 million and generates $13.27 million in revenue each year. The company earns $-5,150,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.

How can I contact Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals' mailing address is 645 MOLLY LANE SUITE 150, WOODSTOCK GA, 30189. The official website for the company is www.sonomapharma.com. The company can be reached via phone at (800) 759-9305, via email at dmcfadden@sonomais.com, or via fax at 707-283-0551.

This page (NASDAQ:SNOA) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -